FDA gives Zydus Cadila's generic Belviq tentative approval

Zydus Cadila has received the Food and Drug Administration’s tentative nod for lorcaserin hydrochloride tablets in a dosage strength of 10 mg.

The product is the generic of Eisai’s Belviq tablets, 10 mg.

The drug is used together with diet and exercise to treat obesity and will be manufactured at the group’s formulations manufacturing facility at SEZ.